Medtronic launches MiniMed split-off. Analysts give Medtronic stock 19 Buy ratings
Published on 10/07/2026 at 09:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Medtronic plc (ISIN IE00BTN1Y115) was trading at EUR 77.86 at Lang & Schwarz on October 7, 2026 at 9:08 a.m. CEST, up 0.69 percent versus the prior close of EUR 77.33. The company launched an exchange offer for its MiniMed diabetes unit on September 14, 2026, while analysts counted 19 Buy ratings on October 6, 2026.
MiniMed split-off sets the near-term test
According to FinanzNachrichten on September 14, 2026, Medtronic began an offer to split off at least 80.10 percent of MiniMed. Participating shareholders can exchange Medtronic ordinary shares for MiniMed shares at a 7.00 percent discount, subject to an upper limit of 4.5939 MiniMed shares for each Medtronic share accepted.
The offer was scheduled to expire on October 9, 2026, unless extended or terminated, and required at least 112,680,647 MiniMed shares to be issued. That structure makes the exchange ratio and participation level the immediate variables for shareholders assessing the separation.
Revenue growth exceeds the guidance range
Yahoo Finance reported on October 1, 2026 that Medtronic delivered USD 9.76 billion of revenue in the first quarter of fiscal 2027, up 13.70 percent from the prior year. Adjusted earnings per share rose 15.10 percent to USD 1.45 and exceeded consensus by 4.30 percent, while GAAP earnings per share increased 40.70 percent to USD 1.14.
Management raised fiscal 2027 organic revenue growth guidance to 7.25 percent to 7.75 percent from 6.75 percent to 7.25 percent, and lifted adjusted earnings per share guidance to USD 5.94 to USD 6.00 from USD 5.90 to USD 6.00. The quarter also included an extra fiscal week, a timing factor that limits a direct comparison with every later quarter.
Analyst optimism meets a lower quote
MarketBeat reported on October 6, 2026 that 19 analysts rated Medtronic Buy and 9 rated it Hold, producing a Moderate Buy consensus and an average target of USD 103.92. The same report cited a quarterly dividend of USD 0.72 per share, with payment scheduled for October 16, 2026.
MarketWatch listed November 24, 2026 as the expected date for Medtronic's second-quarter fiscal 2027 earnings. For investors, the key contrast is clear: reported revenue growth reached 13.70 percent, while the full-year organic growth outlook stands at 7.25 percent to 7.75 percent.
Medtronic stock stays below its US high
Medtronic's primary listing is on the NYSE, where finance data showed an October 6, 2026 price of USD 87.09 and a 52-week range of USD 73.31 to USD 106.33. The same quote set indicated a market capitalization of USD 111.5 billion, while the Lang & Schwarz euro quote remained an intraday indication for German investors.
The further course of trading is shown by the continuously updated real-time quote of Medtronic stock.
Medtronic stock facts
- Company: Medtronic plc
- ISIN: IE00BTN1Y115
- Ticker: MDT
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 7, 2026, 9:08 a.m. CEST: EUR 77.86
- Change versus prior close: plus 0.69 percent
- Prior close Lang & Schwarz October 6, 2026: EUR 77.33
- Market capitalization: USD 111.5 billion as of October 6, 2026
- 52-week range: USD 73.31-106.33 as of October 6, 2026
- Sector / Industry: Healthcare / Medical Devices
- Index membership: S&P 100
- Next earnings date: November 24, 2026
